10 April 2025 - Self-injection provides generalised myasthenia gravis and chronic inflammatory demyelinating polyneuropathy patients with flexibility for when and where to receive treatment – at home, while ‘on the go’ or in a healthcare setting.

argenx today announced that the US FDA approved a new option for patients to self-inject Vyvgart Hytrulo with a pre-filled syringe (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult patients with generalised myasthenia gravis who are anti-acetylcholine receptor antibody positive and adult patients with chronic inflammatory demyelinating polyneuropathy.

Read argenyx press release